View Post

Endoxifen Shows Promise in Treating Breast Cancer in Australian Trial, Development in the US to Accelerate

In Clinical Trials by Barbara Jacoby

By: Ryan McDonald From: curetoday.com Results of a trial assessing endoxifen in patients with breast cancer in Australia were positive enough for the manufacturer to stop the trial before it was scheduled to be completed. The drug’s manufacturer will now accelerate its development in the U.S. Treatment with oral endoxifen during the “window of opportunity” between breast cancer diagnosis and …

View Post

Circulating Tumor Cell Count Reliable in Determining Best Treatment Approach for Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

From: journalofclinicalpathways.com Circulating tumor cell count is a reliable biomarker for choosing between chemotherapy or endocrine therapy for patients with HER2-negative metastatic breast cancer, according to a recent study published in JAMA Oncology (2020 Nov 5. doi:10.1001/jamaoncol.2020.5660). “The choice between chemotherapy and endocrine therapy as first-line treatment for [HER2-negative] metastatic breast cancer is usually based on the presence of clinical …

View Post

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monotherapy in approximately 60 non-elderly patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Cohort …

View Post

Better Outcomes for PIK3CA-Mutated TNBC vs Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: oncnet.com In assessing the treatment landscape for PIK3CA-mutated breast cancer, researchers observed that patients with PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative breast cancer have poorer outcomes and more resistance to chemotherapy than those with PIK3CA-mutated triple-negative breast cancer (TNBC; Ann Oncol. 2020;31[3]:377-386). Although PI3K inhibitors have been shown to improve outcomes in patients with PIK3CA-mutated, HR-positive, HER2-negative metastatic breast cancer, …

View Post

Eli Lilly, Sermonix Pharma Partner on Phase II Trial of Drug Combo in Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Columbus, Ohio-based Sermonix Pharmaceuticals said on Wednesday that it is collaborating with Eli Lilly in an upcoming Phase II trial studying Sermonix’s lasofoxifene in combination with Lilly’s CDK 4 and 6 inhibitor abemaciclib (Verzenio) in estrogen receptor-positive, HER2-negative metastatic breast cancer patients who also harbor an ESR1 mutation. The trial, which is expected to start …

View Post

Quantum Leap Healthcare Collaborative™ announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study

In Clinical Trials by Barbara Jacoby

Source: PR Newswire From: yahoo.com Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an evaluation of SAR439859, an oral estrogen receptor degrader (SERD) in a new I-SPY 2 study arm targeting patients with newly diagnosed hormone receptor-positive (HR+) clinical stage 2/3 invasive breast cancer. This study arm, known as the I-SPY-2 Endocrine Optimization Pilot Protocol (EOP), is focused on patients …

View Post

Improving Upon Treatment Standards in HR+ Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com In an interview with Targeted Oncology, Erica Mayer, MD, discussed advances in the treatment landscape of HR-positive, HER2-negative breast, primarily with endocrine therapy and CDK4/6 inhibition. Treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer is traditionally executed with the use of endocrine therapy. With the emergence of targeted therapies for the treatment of this disease, …

View Post

Immunotherapy improves outcome in high-risk, HER2-negative breast cancer

In Clinical Trials by Barbara Jacoby

By: Megan Brooks From: reuters.com Adding the immune-checkpoint inhibitor durvalumab and the PARP inhibitor olaparib to standard neoadjuvant chemotherapy may improve outcome in women with high-risk, HER2-negative breast cancer, according to results of the I-SPY 2 trial. The benefit was apparent in both the hormone-receptor-positive (HR+) and triple-negative breast cancer (TNBC) subgroups. The I-SPY 2 study enrolled women with high-risk, …

View Post

Durvalumab regimen improves pathologic complete response in HER2-negative breast cancer

In Clinical Trials by Barbara Jacoby

From: healio.com Durvalumab and olaparib in combination with paclitaxel significantly improved pathologic complete response compared with chemotherapy alone among women with stage II or stage III high-risk, HER2-negative breast cancer, according to results of the randomized phase 2 I-SPY 2 study presented at the virtual American Association for Cancer Research Annual Meeting. Researchers observed improvement among subsets of women with …

View Post

Homing in on Targeted Treatment Strategies in Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour From: onclive.com The fields of early-stage hormone receptor (HR)–positive and metastatic HER2-positive breast cancer have made great strides in recent years, said Neelima Denduluri, MD, and such progress could be attributed to the emergence of tailored treatment strategies and the use of HER2-directed agents, respectively. “We’re making great headway in [the treatment of patients with] breast cancer. …